

VEGF R2/KDR

Catalog # PVGS1815

Product Information

Primary Accession Species	P35968-1 Human
Sequence	Ala20-Glu764
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μ g by the LAL method.
Biological Activity	Immobilized Human VEGF165 at 1 μ g/ml (100 μ l/well) on the plate can bind VEGF R2/KDR mFc Chimera, Human (Cat.No.: Z03966)
Expression System	HEK293
Theoretical Molecular Weight	110 kDa
Formulation	Lyophilized from a 0.22 μ m filtered solution in PBS, (pH 7.4).
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O more than 100 μ g/ml.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	Vascular endothelial growth factor receptor 2 (VEGFR2) is one kind of tyrosine kinase receptors. VEGFR2 acts as a cell-surface receptor for VEGFA, VEGFB and PGF. It plays an important role in the development of embryonic vasculature, cell survival and cancer cell invasion. VEGFR2 is a key regulator of angiogenesis.
--------------------------	--

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.